Please use this identifier to cite or link to this item:
Title: Lung function trajectory and biomarkers in the Tasmanian Longitudinal Health Study.
Austin Authors: Bui, Dinh S;Agusti, Alvar;Walters, Haydn;Lodge, Caroline;Perret, Jennifer L ;Lowe, Adrian;Bowatte, Gayan;Cassim, Raisa;Hamilton, Garun S;Frith, Peter;James, Alan;Thomas, Paul S;Jarvis, Debbie;Abramson, Michael J;Faner, Rosa;Dharmage, Shyamali C
Affiliation: Institute for Breathing and Sleep
Dept of Pulmonary Physiology and Sleep Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia
School of Public Health & Preventive Medicine, Monash University, Melbourne, Australia
Respiratory Epidemiology and Public Health Group, National Heart and Lung Institute, Imperial College London, London, UK
Allergy and Lung Health Unit, School of Population and Global Health, The University of Melbourne, Melbourne, Australia
Lung and Sleep Dept at Monash Health, Melbourne, Australia
School of Clinical Sciences, Monash University, Melbourne, Australia
College of Medicine and Public Health, Flinders University, Adelaide, Australia
Dept of Epidemiology and Biostatistics, MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London, UK
Faculty of Medicine, Inflammation and Infection Research, University of New South Wales, Sydney, Australia
Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Barcelona, Spain
Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Respiratory Institute, Hospital Clinic, Barcelona, Spain
University of Barcelona, Barcelona, Spain
Issue Date: 13-Sep-2021 2021-07
Publication information: ERJ Open Research 2021; 7(3): 00020-2021.
Abstract: Different lung function trajectories through life can lead to COPD in adulthood. This study investigated whether circulating levels of biomarkers can differentiate those with accelerated (AD) from normal decline (ND) trajectories. The Tasmanian Longitudinal Health Study (TAHS) is a general population study that measured spirometry and followed up participants from ages 7 to 53 years. Based on their forced expiratory volume in 1 s (FEV1) trajectories from age 7 to 53 years, this analysis included those with COPD at age 53 years (60 with AD and 94 with ND) and controls (n=720) defined as never-smokers with an average FEV1 trajectory. Circulating levels of selected biomarkers determined at 53 and 45 years of age were compared between trajectories. Results showed that CC16 levels (an anti-inflammatory protein) were lower and C-reactive protein (CRP) (a pro-inflammatory marker) higher in the AD than in the ND trajectory. Higher CC16 levels were associated with a decreased risk of belonging to the AD trajectory (OR=0.79 (0.63-0.98) per unit increase) relative to ND trajectory. Higher CRP levels were associated with an increased risk of belonging to the AD trajectory (OR=1.07, 95% CI: 1.00-1.13, per unit increase). Levels of CC16 (area under the curve (AUC)=0.69, 95% CI: 0.56-0.81, p=0.002), CRP (AUC=0.63, 95% CI: 0.53-0.72, p=0.01) and the combination of both (AUC=0.72, 95% CI: 0.60-0.83, p<0.001) were able to discriminate between the AD and ND trajectories. Other quantified biomarkers (interleukin (IL)-4, IL-5, IL-6, IL-10 and tumour necrosis factor-α (TNF-α)) were not significantly different between AD, ND and controls. Circulating levels of CRP and CC16 measured in late adulthood identify different lung function trajectories (AD versus ND) leading to COPD at age 53 years.
DOI: 10.1183/23120541.00020-2021
ORCID: 0000-0002-4388-784X
Journal: ERJ Open Research
PubMed URL: 34527727
PubMed URL:
ISSN: 2312-0541
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jun 7, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.